Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Alembic Pharma opens...

    Alembic Pharma opens Rs 300 crore anti-cancer drug unit in Gujarat

    Written by Ruby Khatun Khatun Published On 2017-07-16T10:03:02+05:30  |  Updated On 16 July 2017 10:03 AM IST

    VADODARA: Drug firm Alembic Pharmaceuticals Ltd (APL) entered into oncology segment by inaugurating a Rs 300 crore anti-cancer drug facility at Halol in Gujarat.


    Speaking on the occasion, Chirayu Amin chairman of Alembic group of companies said the Rs 300 crore unit will manufacture 60 million tablets/capsules and approximately 20 million vials of liquid injectable and lyophilized concentrates.


    Gujarat Chief Minister Vijay Rupani after inaugurating plant said, "Gujarat is a leading producer with 80 per cent of pharmaceuticals products in the country and our government encourages more R&D spending for new drug discovery."


    The state government hopes to launch 1,000 generic medical stores in 2017 from the present 250 stores, which will help in providing cheap quality drugs to people of the state, Rupani said.


    He also said that Gujarat have been receiving lot of investment enquiries from global investors and we will provide conducive investment environment through new policies.


    With this facility, the Alembic Pharma will commence exporting oncology products to US, Middle East, North Africa, Australia and South Africa, Amin said.


    The facility has equipment from BOSCH of Germany, GEA of Belgium, Alexanderwerk from UK, ICOS from Italy, Tofflon from China.


    APL managing director Pranav Amin said the company hopes to invest Rs 1,500 crore as part of its expansion plan over the next three years period, which will be funded through debt and internal accruals.


    APL has recently invested in an ultra-modern R&D centre at Hyderabad. APL is one of the leading players in the industry to have invested about 11 per cent of its turnover in R&D, Amin said.

    Alembic PharmaAlembic PharmaceuticalsAnti cancer drugsanti-cancer drug unitChirayu AminGujaratGujarat Chief Ministerliquid injectablelyophilized concentratesoncologyopenVijay Rupani
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok